Latest Manufacturing Capacity News

Advanced Innergy Holdings Ltd (ASX:AIH) has reported a robust FY25 performance highlighted by a successful IPO and strong growth across its core segments, setting a confident tone for FY26.

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.

Amotiv Limited reported a solid FY26 half-year result with revenue growth and margin pressures partly offset by its Amotiv Unified transformation program. The company maintained its FY26 guidance, highlighting strong cash flow and shareholder returns.

Vmoto Limited reports a robust sales rebound in the final quarter of 2025, with a 68% jump in units sold and a near doubling of firm orders, underpinned by strategic partnerships and expanding manufacturing capacity.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

Little Green Pharma Ltd is set to acquire Cannatrek Ltd in a transformative merger that will create one of the largest vertically integrated medicinal cannabis companies globally, with pro-forma FY25 revenue exceeding AUD 112 million.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

Merino & Co. reported steady progress in Q2 FY26 with growing demand from China and ongoing investments in brand and manufacturing, despite a tightening cash position.

Elders Limited delivered a resilient FY25 performance with 12% EBIT growth and a strategic focus on diversification and leverage reduction. The company’s Fourth Eight Point Plan drives operational optimisation and expansion across agribusiness divisions.

NeuroScientific Biopharmaceuticals has reported promising initial clinical responses from its StemSmart™ Special Access Program treating Fistulising Crohn’s Disease, while preparing for a pivotal Phase 2 trial in 2026.